Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                 ARM A
                                                                                 (N=30)
                                                                  ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
      System Organ Class
         Preferred Term                                              Mild        Mod**      Severe
      ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

All System Organ Classes
         All Adverse Events                                       22 ( 73.3%) 8 ( 26.7%)  0 (  0.0%)

Gastrointestinal disorders
         Cheilitis                                                0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Diarrhoea                                                1 (  3.3%)  0 (  0.0%)  0 (  0.0%)
         Stomach Discomfort                                       1 (  3.3%)  0 (  0.0%)  0 (  0.0%)
         Toothache                                                1 (  3.3%)  0 (  0.0%)  0 (  0.0%)

General disorders and administration site conditions
         Application Site Erythema                                0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Influenza Like Illness                                   0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Hepatobiliary disorders
         Gallbladder Disorder                                     0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Infections and infestations
         Bronchitis                                               0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Nail Infection                                           0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Paronychia                                               0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Rash Pustular                                            1 (  3.3%)  0 (  0.0%)  0 (  0.0%)
         Respiratory Tract Infection                              1 (  3.3%)  0 (  0.0%)  0 (  0.0%)
         Rhinitis                                                 0 (  0.0%)  1 (  3.3%)  0 (  0.0%)
         Sinusitis                                                0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Date Produced: Time ;  Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                    Page 1 of 12
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                 ARM B
                                                                                 (N=19)
                                                                  ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
      System Organ Class
         Preferred Term                                              Mild        Mod**      Severe
      ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

All System Organ Classes
         All Adverse Events                                       9 ( 47.4%)  10 ( 52.6%) 0 (  0.0%)

Gastrointestinal disorders
         Cheilitis                                                0 (  0.0%)  1 (  5.3%)  0 (  0.0%)
         Diarrhoea                                                0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Stomach Discomfort                                       0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Toothache                                                0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

General disorders and administration site conditions
         Application Site Erythema                                1 (  5.3%)  0 (  0.0%)  0 (  0.0%)
         Influenza Like Illness                                   0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Hepatobiliary disorders
         Gallbladder Disorder                                     0 (  0.0%)  1 (  5.3%)  0 (  0.0%)

Infections and infestations
         Bronchitis                                               0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Nail Infection                                           0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Paronychia                                               0 (  0.0%)  1 (  5.3%)  0 (  0.0%)
         Rash Pustular                                            0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Respiratory Tract Infection                              0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Rhinitis                                                 0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Sinusitis                                                1 (  5.3%)  0 (  0.0%)  0 (  0.0%)

Date Produced: Time ;  Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                    Page 2 of 12
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                 ARM C
                                                                                 (N=10)
                                                                  ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
      System Organ Class
         Preferred Term                                              Mild        Mod**      Severe
      ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

All System Organ Classes
         All Adverse Events                                       4 ( 40.0%)  6 ( 60.0%)  0 (  0.0%)

Gastrointestinal disorders
         Cheilitis                                                0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Diarrhoea                                                0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Stomach Discomfort                                       0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Toothache                                                0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

General disorders and administration site conditions
         Application Site Erythema                                0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Influenza Like Illness                                   1 ( 10.0%)  0 (  0.0%)  0 (  0.0%)

Hepatobiliary disorders
         Gallbladder Disorder                                     0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Infections and infestations
         Bronchitis                                               0 (  0.0%)  2 ( 20.0%)  0 (  0.0%)
         Nail Infection                                           0 (  0.0%)  1 ( 10.0%)  0 (  0.0%)
         Paronychia                                               0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Rash Pustular                                            0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Respiratory Tract Infection                              0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Rhinitis                                                 0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Sinusitis                                                0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Date Produced: Time ;  Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                    Page 3 of 12
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                 ARM D
                                                                                 (N=16)
                                                                  ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
      System Organ Class
         Preferred Term                                              Mild        Mod**      Severe
      ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

All System Organ Classes
         All Adverse Events                                       7 ( 43.8%)  8 ( 50.0%)  1 (  6.2%)

Gastrointestinal disorders
         Cheilitis                                                0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Diarrhoea                                                0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Stomach Discomfort                                       0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Toothache                                                0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

General disorders and administration site conditions
         Application Site Erythema                                0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Influenza Like Illness                                   0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Hepatobiliary disorders
         Gallbladder Disorder                                     0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Infections and infestations
         Bronchitis                                               0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Nail Infection                                           0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Paronychia                                               0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Rash Pustular                                            0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Respiratory Tract Infection                              0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Rhinitis                                                 0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Sinusitis                                                0 (  0.0%)  1 (  6.2%)  0 (  0.0%)

Date Produced: Time ;  Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                    Page 4 of 12
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                 ARM A
                                                                                 (N=30)
                                                                  ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
      System Organ Class
         Preferred Term                                              Mild        Mod**      Severe
      ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

         Tinea Pedis                                              0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Upper Respiratory Fungal Infection                       0 (  0.0%)  1 (  3.3%)  0 (  0.0%)
         Upper Respiratory Tract Infection                        1 (  3.3%)  0 (  0.0%)  0 (  0.0%)
         Urinary Tract Infection                                  0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Wound Infection                                          0 (  0.0%)  1 (  3.3%)  0 (  0.0%)

Injury, poisoning and procedural complications
         Fall                                                     0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Heat Cramps                                              1 (  3.3%)  0 (  0.0%)  0 (  0.0%)
         Muscle Injury                                            0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Procedural Pain                                          0 (  0.0%)  1 (  3.3%)  0 (  0.0%)

Investigations
         Blood Potassium Decreased                                0 (  0.0%)  1 (  3.3%)  0 (  0.0%)
         Blood Triglycerides Increased                            1 (  3.3%)  0 (  0.0%)  0 (  0.0%)
         Vitamin D Decreased                                      1 (  3.3%)  0 (  0.0%)  0 (  0.0%)

Musculoskeletal and connective tissue disorders
         Back Pain                                                0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Joint Swelling                                           0 (  0.0%)  1 (  3.3%)  0 (  0.0%)
         Myalgia                                                  0 (  0.0%)  1 (  3.3%)  0 (  0.0%)
         Pain In Extremity                                        1 (  3.3%)  0 (  0.0%)  0 (  0.0%)

Nervous system disorders

Date Produced: Time ;  Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                    Page 5 of 12
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                 ARM B
                                                                                 (N=19)
                                                                  ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
      System Organ Class
         Preferred Term                                              Mild        Mod**      Severe
      ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

         Tinea Pedis                                              0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Upper Respiratory Fungal Infection                       0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Upper Respiratory Tract Infection                        2 ( 10.5%)  0 (  0.0%)  0 (  0.0%)
         Urinary Tract Infection                                  0 (  0.0%)  2 ( 10.5%)  0 (  0.0%)
         Wound Infection                                          0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Injury, poisoning and procedural complications
         Fall                                                     1 (  5.3%)  0 (  0.0%)  0 (  0.0%)
         Heat Cramps                                              0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Muscle Injury                                            0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Procedural Pain                                          0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Investigations
         Blood Potassium Decreased                                0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Blood Triglycerides Increased                            0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Vitamin D Decreased                                      0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Musculoskeletal and connective tissue disorders
         Back Pain                                                0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Joint Swelling                                           0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Myalgia                                                  0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Pain In Extremity                                        0 (  0.0%)  1 (  5.3%)  0 (  0.0%)

Nervous system disorders

Date Produced: Time ;  Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                    Page 6 of 12
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                 ARM C
                                                                                 (N=10)
                                                                  ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
      System Organ Class
         Preferred Term                                              Mild        Mod**      Severe
      ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

         Tinea Pedis                                              0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Upper Respiratory Fungal Infection                       0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Upper Respiratory Tract Infection                        2 ( 20.0%)  0 (  0.0%)  0 (  0.0%)
         Urinary Tract Infection                                  0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Wound Infection                                          0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Injury, poisoning and procedural complications
         Fall                                                     0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Heat Cramps                                              0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Muscle Injury                                            0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Procedural Pain                                          0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Investigations
         Blood Potassium Decreased                                0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Blood Triglycerides Increased                            0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Vitamin D Decreased                                      0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Musculoskeletal and connective tissue disorders
         Back Pain                                                0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Joint Swelling                                           0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Myalgia                                                  0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Pain In Extremity                                        0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Nervous system disorders

Date Produced: Time ;  Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                    Page 7 of 12
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                 ARM D
                                                                                 (N=16)
                                                                  ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
      System Organ Class
         Preferred Term                                              Mild        Mod**      Severe
      ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

         Tinea Pedis                                              0 (  0.0%)  1 (  6.2%)  0 (  0.0%)
         Upper Respiratory Fungal Infection                       0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Upper Respiratory Tract Infection                        1 (  6.2%)  0 (  0.0%)  0 (  0.0%)
         Urinary Tract Infection                                  0 (  0.0%)  1 (  6.2%)  0 (  0.0%)
         Wound Infection                                          0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Injury, poisoning and procedural complications
         Fall                                                     0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Heat Cramps                                              0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Muscle Injury                                            0 (  0.0%)  1 (  6.2%)  0 (  0.0%)
         Procedural Pain                                          0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Investigations
         Blood Potassium Decreased                                0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Blood Triglycerides Increased                            0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Vitamin D Decreased                                      0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Musculoskeletal and connective tissue disorders
         Back Pain                                                1 (  6.2%)  0 (  0.0%)  0 (  0.0%)
         Joint Swelling                                           0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Myalgia                                                  0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Pain In Extremity                                        0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Nervous system disorders

Date Produced: Time ;  Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                    Page 8 of 12
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                 ARM A
                                                                                 (N=30)
                                                                  ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
      System Organ Class
         Preferred Term                                              Mild        Mod**      Severe
      ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

         Burning Sensation                                        0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Dizziness                                                1 (  3.3%)  0 (  0.0%)  0 (  0.0%)
         Headache                                                 10 ( 33.3%) 1 (  3.3%)  0 (  0.0%)
         Sciatica                                                 0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Reproductive system and breast disorders
         Menstrual Discomfort                                     0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Respiratory, thoracic and mediastinal disorders
         Cough                                                    0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Nasal Congestion                                         1 (  3.3%)  0 (  0.0%)  0 (  0.0%)
         Sinus Congestion                                         0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Throat Irritation                                        0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Upper Respiratory Tract Congestion                       0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Skin and subcutaneous tissue disorders
         Erythema                                                 0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Pruritus                                                 0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Skin Discomfort                                          0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Surgical and medical procedures
         Cholecystectomy                                          0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Skin Lesion Excision                                     0 (  0.0%)  0 (  0.0%)  0 (  0.0%)


Date Produced: Time ;  Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                    Page 9 of 12
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                 ARM B
                                                                                 (N=19)
                                                                  ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
      System Organ Class
         Preferred Term                                              Mild        Mod**      Severe
      ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

         Burning Sensation                                        0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Dizziness                                                0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Headache                                                 1 (  5.3%)  1 (  5.3%)  0 (  0.0%)
         Sciatica                                                 0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Reproductive system and breast disorders
         Menstrual Discomfort                                     0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Respiratory, thoracic and mediastinal disorders
         Cough                                                    0 (  0.0%)  1 (  5.3%)  0 (  0.0%)
         Nasal Congestion                                         0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Sinus Congestion                                         0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Throat Irritation                                        0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Upper Respiratory Tract Congestion                       0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Skin and subcutaneous tissue disorders
         Erythema                                                 2 ( 10.5%)  0 (  0.0%)  0 (  0.0%)
         Pruritus                                                 0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Skin Discomfort                                          1 (  5.3%)  0 (  0.0%)  0 (  0.0%)

Surgical and medical procedures
         Cholecystectomy                                          0 (  0.0%)  1 (  5.3%)  0 (  0.0%)
         Skin Lesion Excision                                     0 (  0.0%)  1 (  5.3%)  0 (  0.0%)


Date Produced: Time ;  Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                   Page 10 of 12
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                 ARM C
                                                                                 (N=10)
                                                                  ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
      System Organ Class
         Preferred Term                                              Mild        Mod**      Severe
      ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

         Burning Sensation                                        1 ( 10.0%)  0 (  0.0%)  0 (  0.0%)
         Dizziness                                                0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Headache                                                 0 (  0.0%)  1 ( 10.0%)  0 (  0.0%)
         Sciatica                                                 0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Reproductive system and breast disorders
         Menstrual Discomfort                                     0 (  0.0%)  1 ( 10.0%)  0 (  0.0%)

Respiratory, thoracic and mediastinal disorders
         Cough                                                    0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Nasal Congestion                                         0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Sinus Congestion                                         0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Throat Irritation                                        0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Upper Respiratory Tract Congestion                       0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Skin and subcutaneous tissue disorders
         Erythema                                                 0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Pruritus                                                 0 (  0.0%)  1 ( 10.0%)  0 (  0.0%)
         Skin Discomfort                                          0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Surgical and medical procedures
         Cholecystectomy                                          0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Skin Lesion Excision                                     0 (  0.0%)  0 (  0.0%)  0 (  0.0%)


Date Produced: Time ;  Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                   Page 11 of 12
Client: Experis                                                                                   Study: BBC
                                                 Table 1.0
                                         Adverse Events by Severity
                                             Safety Population

                                                                                 ARM D
                                                                                 (N=16)
                                                                  ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
      System Organ Class
         Preferred Term                                              Mild        Mod**      Severe
      ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

         Burning Sensation                                        0 (  0.0%)  0 (  0.0%)  1 (  6.2%)
         Dizziness                                                0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Headache                                                 0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Sciatica                                                 1 (  6.2%)  0 (  0.0%)  0 (  0.0%)

Reproductive system and breast disorders
         Menstrual Discomfort                                     0 (  0.0%)  0 (  0.0%)  0 (  0.0%)

Respiratory, thoracic and mediastinal disorders
         Cough                                                    0 (  0.0%)  1 (  6.2%)  0 (  0.0%)
         Nasal Congestion                                         0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Sinus Congestion                                         1 (  6.2%)  0 (  0.0%)  0 (  0.0%)
         Throat Irritation                                        1 (  6.2%)  0 (  0.0%)  0 (  0.0%)
         Upper Respiratory Tract Congestion                       1 (  6.2%)  0 (  0.0%)  0 (  0.0%)

Skin and subcutaneous tissue disorders
         Erythema                                                 0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Pruritus                                                 1 (  6.2%)  2 ( 12.5%)  0 (  0.0%)
         Skin Discomfort                                          0 (  0.0%)  1 (  6.2%)  0 (  0.0%)

Surgical and medical procedures
         Cholecystectomy                                          0 (  0.0%)  0 (  0.0%)  0 (  0.0%)
         Skin Lesion Excision                                     0 (  0.0%)  0 (  0.0%)  0 (  0.0%)


Date Produced: Time ;  Program: Table3_0.R
* Total Reporting is defined as number of subjects who reported at least one adverse event.
** Mod = Moderate
# Episodes is defined as the total number of occurances of adverse events
% is defined as Number of Subjects divided by Total Reporting
Note: Adverse events were coded using MedDRA Version 9.1

Time                                            Confidential                                   Page 12 of 12
